The use of surrogate and composite endpoints, disease-specific mortality as an endpoint, and relative (rather than absolute) risk reporting in clinical trials may produce results that are misleading or difficult to interpret. OBJECTIVE: To describe the prevalence of these endpoints and of relative risk reporting in medication trials.
INTRODUCTION
Medical interventions are judged as successes or failures in clinical studies based on their impact on the study endpoints. Because interventions have a variety of effects, and may appear effective using one set of endpoints but harmful using another set, the selection of endpoints is critical. 1 Recently, there have been growing concerns about the selection of endpoints and the reporting of results in clinical trials. In particular, experts have suggested that the use of surrogate endpoints, [2] [3] [4] [5] [6] and composite endpoints, [7] [8] [9] [10] [11] and the use of disease-specific-rather than all-cause-mortality as an endpoint, 12, 13 may mislead readers if the limitations of these endpoints are not adequately explained. Similar concerns have also been raised about the reporting of trial results in relative-rather than absolute-numbers, Table 1 describes these concerns. A limited number of studies have examined the prevalence of the use of surrogate [3] [4] [5] and composite endpoints 7, 9, 16 the use of disease specific mortality as an endpoint 12, 17 and the reporting of results in relative numbers 14, 18, 19 in clinical trials. However, data from these studies are several years old, typically reflect trials involving treatments for only a limited spectrum of diseases, and provide only limited details about factors that may be associated with these endpoints and with relative risk reporting. In this study we examine the prevalence of the use of surrogate endpoints, composite endpoints, disease-specific mortality as an endpoint, and the use of relative risk reporting in recently published medication trials from the six highest impact general medicine and internal medicine journals. We also examine the association between trial funding source and outcome (i.e. positive vs. negative results) and these trial characteristics.
METHODS
Details of the process by which studies were identified have previously been published. 20 In summary, we identified all randomized trials involving medications that reported on at least one pre-specified primary endpoint published in the 28-month period between June 1, 2008, and September 30, 2010, in the 6 general medicine and internal medicine journals with the highest impact factor (New England Journal of Medicine, Lancet, JAMA, Annals of Internal Medicine, BMJ, and Archives of Internal Medicine). 21 One author (M.H.) performed the literature review, abstracted information from included studies, and characterized each study with regard to outcomes of interest according to pre-specified criteria (outlined below and in the Appendix-available online). The studies were identified by manually reviewing all original articles with a formal abstract published during the specified time period. All randomized trials involving humans in which systemically active medications (either a specific medication or a class of medications) were compared with either an active treatment (such as another medication or a non-pharmacologic therapy) or an inactive control (either a placebo or no therapy) were selected for inclusion. Phase 1 and phase 2 trials were excluded since these studies are preliminary assessments, and are not generally powered to assess clinically important endpoints. Trials that were not assigned to a phase were excluded if there were fewer than 100 subjects, since many of these trials would likely have been classified as phase 1 or 2 trials (only seven trials fit into this category and inclusion of these studies did not affect the overall study results).
DETERMINING STUDY CHARACTERISTICS
Each selected study was reviewed to determine the sample size, the trial phase (i.e. phase 3 or 4 or unassigned as reported either in the text of the study, the trial registry, or both), whether the study was commercially funded (i.e. received funding aside from free study medications from a for-profit company according to the Methods or Acknowledgements section), whether the study received funding from a government agency (either in the United States or another country according to the Methods or Acknowledgements section), whether the trial was an active comparator vs. inactive comparator trial, whether a non-inferiority data analysis (either alone or in addition to a superiority analysis) was performed, and whether the study medications were US Food and Drug Administration (FDA)-approved when trial enrollment began. Trials were also reviewed to determine if there was a statistically significant positive result (i.e. a favorable result such as better efficacy or a lower rate of adverse events) for the newer therapy relative to the control group with regard to any primary trial endpoint. Trials were considered ineligible for this latter analysis if there were three or more treatment groups because, in these cases, it was not possible to determine which two groups should be considered when determining if there was a positive result. In addition, trials comparing different medication administration strategies were considered ineligible since it was not clear which treatment arm represented the "newer" therapy.
In addition to the above characterizations, the primary endpoint(s) of each trial-as indicated in the article or, if not indicated in the article, as indicated in the trial registry-were reviewed to determine whether they were surrogate vs. clinical endpoints, whether they were composite endpoints, whether any primary endpoint involved disease-specific mortality or allcause mortality, and whether the primary endpoint analyses were reported in the abstract exclusively using relative rather than absolute numbers (i.e. the trial was categorized as reporting results in relative terms only if all references to the result in the abstract were in relative numbers; relative vs. absolute reporting in the main article text was not assessed). The latter determination was only made for trials with positive results since relative risk reporting is most problematic when it causes an intervention to appear more effective than it actually is.
Further details of how surrogate and composite endpoints were classified are available in the Appendix (available online). Briefly, we defined surrogate endpoints as those using "a laboratory measurement or a physical sign used as a substitute for a clinically meaningful outcome that measures directly how a patient feels, functions or survives." 22, 23 This judgment was made by the reviewing author. Prior 
QUALITY CONTROL ASSESSMENT
Because of the potential subjectivity in determining whether trial endpoints should be classified as surrogate vs. clinical endpoints, a quality control review was performed. One author (D.M.) independently reviewed all studies published during the 2nd, 6th, 10th, 14th, 18th, 22nd, and 26th months of the 28-month study period and independently classified studies with regard to the use of surrogate vs. clinical endpoints. Unlike the primary data extractor (M.H.), D.M. was blinded to each study's funding source during the quality control review. Inter-rater agreement was assessed by calculating a κ statistic. Differences were not reconciled since the quality check was only performed on a subset of studies. For all analyses reported in this paper, M.H.'s determinations were used.
STATISTICAL ANALYSIS
We tested for associations between trial funding source and the use of each of the examined trial endpoints, as well as for associations between trial funding source and relative risk reporting. We also tested for associations between trial results (i.e. whether the trial had statistically significant positive results with respect to the newer therapy) and the use of each examined endpoint. Since we only examined relative risk reporting among trials with positive results, it was not possible to test for associations between the use of relative risk reporting and trial results. We used two-sided χ 2 tests with an a priori level of significance of P≤ 0.05 to test for all of the above associations. All of the above analyses were pre-specified. We performed post-hoc calculations using two-tailed tests with an α level of 0.05 to assess the power of our study to detect statistically significant associations between the use of each examined trial characteristic and the reliance on exclusive commercial funding. We based these calculations on the actual prevalence of each endpoint, and we calculated the power to detect an absolute difference of 15% (e.g. if the prevalence of a particular endpoint was 30%, we determined the power to detect a difference in the use of that endpoint between commercially and non-commercially funded of 22.5% vs. 37.5%). The power to detect a significant difference for commercially vs. non-commercially funded trials for each characteristic was: 79% for surrogate endpoints; 81% for composite endpoints; 96.5% for multiple primary endpoints; 79% for any mortality endpoint; 41% for disease-specific mortality vs. all-cause mortality; and 45% for relative risk reporting.
We also performed post-hoc power calculations using twotailed tests with an α level of 0.05 to assess the power of our study to detect statistically significant associations between a trial's outcome (i.e. positive vs. negative/neutral results) and the use of each examined endpoint. We based these calculations on the actual prevalence of positive results, 55%, and we calculated the power to detect an absolute difference of 15% (i.e. a rate of positive results of 47.5% among trials using a particular endpoint and a rate of positive results of 62.5% among trials not using that endpoint). The power to detect a significant difference was: 69% for surrogate endpoints; 68% for composite endpoints; 40% for multiple primary endpoints; 70% for any mortality endpoint; and 29% for disease-specific mortality vs. all-cause mortality.
All statistical analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, North Carolina) or STATA version 11.0 (StataCorp LP, College Station, Texas).
RESULTS
2,592 original articles were reviewed in the 6 medical journals, of which 316 reported on a pre-specified primary endpoint and were eligible for the analysis. Characteristics of these 316 trials are shown in Table 2 . Table 3 shows the percentage of trials using each type of endpoint as well as the percentage reporting results in the Table 4 shows the relationship between each of the examined endpoints and the trial results (positive vs. negative with respect to the newer therapy). Trials using surrogate endpoints were more likely to report positive results (66% vs. 49%, difference 17% [95% CI 5%-28%], P=0.006) while those using mortality endpoints were less likely to be positive (46% vs. 62%, difference −16% [95% CI −27% -−4%], P=0.01). In addition, trials using composite endpoints were less likely to generate positive results (47% vs. 60%, difference −12% [95% CI −24% -0.0%], P=0.05), though this difference was of borderline statistical significance.
Among the 106 trials using a composite endpoint, 86 (81%) included a mortality endpoint (either disease-specific or allcause) as part of the composite, while 30 (28%) included a surrogate endpoint as part of the composite. Among the 118 trials using a mortality endpoint, in 86 cases (73%) the mortality endpoint was part of a composite.
A total of 67 of the 316 trials were analyzed for the quality control review, and there was agreement between the primary data analysis and the quality review for 59 trials with regard to classification of the primary trial endpoint as surrogate vs. clinical (88%; 95% CI, 80%-96% [κ 0.76; 95% CI, 0.61-0.92]).
DISCUSSION
Among 316 randomized trials published in top medical journals, 37% used surrogate endpoints and 34% used composite endpoints. Among trials using mortality as an endpoint, 27% used disease-specific mortality rather than all-cause mortality. In addition, 44% of trials reported results in the abstract exclusively in relative numbers. Our study represents the largest and most comprehensive analysis of trial endpoints and relative risk reporting that we are aware of. The results of several smaller analyses are summarized in Table 5 .
We believe the high prevalence of these endpoints is notable because it demonstrates the complexity of interpreting medical research for patients, doctors, and policy makers. Without appropriate explanation of the limitations of these endpoints, readers may draw inappropriate conclusions. Determination of whether articles adequately explained the limitations was beyond the scope of our analysis.
Despite the concerns with these endpoints, however, we do not intend to suggest that these endpoints should never be used. An important advantage of these endpoints is that they frequently increase the power of a study to detect significant Applies to the 157 trials reporting statistically significant positive results, 100 of which received exclusive commercial funding, 57 of which received noncommercial funding (i.e. at least some funding from a non-commercial entity), 45 of which received government funding, and 112 of which did not receive government funding associations (the reasons for this are described in Table 1 ). For this reason, these endpoints are generally appropriate in early phase studies in which investigators seek preliminary data to rapidly assess safety and efficacy. These endpoints may also be appropriate in some advanced phase trials of therapies for rare diseases or in low risk populations in which it may be too expensive or impractical to recruit sufficient patients to achieve adequate statistical power. In our study, we did not attempt to assess whether or not articles that used these endpoints did so appropriately because of the difficulty of making this determination. However, by only including advanced phase studies, we excluded many studies in which the use of these endpoints is likely to be appropriate. 6 Another notable finding of our study is that authors commonly report trial results exclusively in relative terms despite a growing recognition that relative risk reporting can distort the magnitude of the effects of an intervention. 13, 14, 18, 19 Given these concerns, readers are likely to be better served by uniform inclusion of absolute risk reporting. We also found that trials receiving exclusive commercial funding were more likely than those receiving non-commercial funding to use surrogate endpoints and to use disease-specific mortality as an endpoint. We speculate that commercially funded trials-compared with non-commercially funded trials -tend to select endpoints such as surrogate markers and disease-specific mortality that are perceived to have a higher likelihood of generating statistically significant results. As noted above, however, it is possible that some of the commercially funded trials in our analysis that used these endpoints did so appropriately.
Our analysis also showed that trials using surrogate endpoints were more likely than trials using clinical endpoints to generate positive results. This is notable because several recent studies have shown that interventions that have apparently beneficial effects on surrogate markers of disease often do not also have beneficial effects on clinical endpoints 2 . For this reason, positive trials that use surrogate endpoints may inappropriately promote the use of medications that do not have important clinical benefits. 24 These finding support recent attempts by the FDA to avoid granting drug approvals based on the results of trials using surrogate endpoints. 25 In addition, our finding that surrogate endpoints are more common among commercially funded trials may help explain why commercially funded research is more likely to generate positive results than non-commercially funded research 4, [26] [27] [28] We also found that trials using mortality endpoints were less likely than those not using mortality endpoints to generative positive results, while those using composite endpoints were less likely to generate positive results. The former finding was expected since developing a medication that reduces mortality is presumably more difficult than developing a medication that has beneficial effects on a surrogate endpoint or a more subjective clinical endpoint such as symptom control. However, the latter was unexpected since composite endpoints are frequently used to increase the power of a study to detect significant findings. 7, 10 One possible explanation is that a disproportionately high percentage-81%-of trials using a composite endpoint included a mortality endpoint as part of the composite. Since mortality endpoints were associated with negative/neutral results, the low rate of positive findings among trials using composite endpoints may result from the fact that mortality endpoints were used disproportionately. Alternatively, 16 A study of cardiovascular trials published in 14 top journals between 2000-2007 showed that 37% used composite endpoints. Trials using composite endpoints were more likely to report P-values of <0.05 than they were to report nonsignificant P-values, but whether the significant P-value referred to a positive vs. negative result with respect to the newer therapy was not specified. In addition, the study did not report whether trials using composite endpoints were more or less likely than trials not using composite endpoints to report significant results. Therefore, it is not clear that these results contradict our finding that trials using composite endpoints are less likely than trials not using composite endpoints to show positive results Disease-Specific Mortality Kip et al. 17 An analysis of 20 trials comparing bare metal vs.
drug-eluting stents showed that 55% used cardiovascular mortality as an endpoint while 45% used all-cause mortality; another analysis reported in the same paper showed that, among 27 trials published in 2006 in the Journal of the American College of Cardiology, 19% used cardiovascular death as an endpoint while 74% used all-cause mortality Relative Risk Reporting Nuovo et al. 14 Fewer than 10% of trials published in top medical journals prior to 1998 reported risk reductions in absolute terms anywhere in the article Dryver et al. 18 Among articles published in eight journals in 1996, 12% of the abstracts provided a measure of absolute risk difference; no abstracts published in these journals in 1986 did Schwartz et al. 19 Among articles published in 2003 and 2004 in six top journals, 68% of failed to report the underlying absolute risks for the first ratio measure in the abstract and especially since this finding was of borderline significance, the association may represent a chance occurrence. We did not detect other associations between trial funding and endpoint selection or relative risk reporting or between endpoint selection and trial outcomes, however our power to detect some of these associations was limited.
Finally, we found that 81% of trials using a composite endpoint included mortality as part of the composite while 28% included a surrogate marker. These findings suggest that composite endpoints commonly consist of components of varying clinical importance, which may mislead readers. 7, 10, 29 For example, if an intervention reduces the composite rate of death, an endpoint with high clinical importance, and coronary revascularization, an endpoint with lower importance, it may not be clear whether the positive result is driven by a reduction in death, revascularization, or both. There are several limitations to our study. First, our study only focused on medication trials. Second, we only included studies published in the most prominent general medicine and internal medicine journals. Third, our analysis only examined primary trial endpoints. Fourth, we only examined relative risk reporting in trial abstracts. Fifth, the author who extracted the data was not blinded to each study's funding source. Finally, the determination of surrogate vs. clinical endpoints, although made using predefined objective criteria, was only made by one author. In this regard, we are reassured by the high concordance between the clinical vs. surrogate assessments made by the abstracting author and the author whose quality control check was blinded.
Overall, our study shows that the use of surrogate and composite endpoints and endpoints involving disease-specific mortality is common. In addition, articles frequently report results in relative numbers. These findings highlight the need for educational efforts to ensure that readers understand the complexities of these endpoints and of relative risk reporting. A number of recent reports describing the appropriate interpretation of surrogate and composite endpoints, 22, 30, 31 and of relative risk reporting 32 could serve as guides for these efforts. In addition, Institutional Scientific Review Committees and regulatory agencies (e.g. the FDA) must closely examine the endpoints used in clinical trials and discourage the inappropriate use of surrogate and composite endpoints, and endpoints involving disease-specific mortality. Finally, medical journals may consider instituting editorial policies mandating the reporting of results in absolute numbers.
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